Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, Maarten P van den Berg, Bouke PC Hazenberg, Peter van der Meer
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/95b6495b7e1045f9870bb1ae57637de7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:95b6495b7e1045f9870bb1ae57637de7
record_format	dspace
spelling	oai:doaj.org-article:95b6495b7e1045f9870bb1ae57637de72021-12-04T16:03:22ZCardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?10.15420/cfr.2019.162057-75592057-7540https://doaj.org/article/95b6495b7e1045f9870bb1ae57637de72020-08-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2019.16https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of cardiac ATTR amyloidosis is strong if pronounced left ventricular hypertrophy is present in the absence of hypertension. Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. First treatment options for ATTR amyloidosis recently emerged, and showed a reduction in morbidity and mortality, especially if treatment was started in the early stages of disease. In light of these results, screening for ATTR amyloidosis in the general HFpEF population with left ventricular hypertrophy might be useful.Sebastiaan HC KlaassenDirk J van VeldhuisenHans LA NienhuisMaarten P van den BergBouke PC HazenbergPeter van der MeerRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 6, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Sebastiaan HC Klaassen Dirk J van Veldhuisen Hans LA Nienhuis Maarten P van den Berg Bouke PC Hazenberg Peter van der Meer Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
description	Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of cardiac ATTR amyloidosis is strong if pronounced left ventricular hypertrophy is present in the absence of hypertension. Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. First treatment options for ATTR amyloidosis recently emerged, and showed a reduction in morbidity and mortality, especially if treatment was started in the early stages of disease. In light of these results, screening for ATTR amyloidosis in the general HFpEF population with left ventricular hypertrophy might be useful.
format	article
author	Sebastiaan HC Klaassen Dirk J van Veldhuisen Hans LA Nienhuis Maarten P van den Berg Bouke PC Hazenberg Peter van der Meer
author_facet	Sebastiaan HC Klaassen Dirk J van Veldhuisen Hans LA Nienhuis Maarten P van den Berg Bouke PC Hazenberg Peter van der Meer
author_sort	Sebastiaan HC Klaassen
title	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
title_short	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
title_full	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
title_fullStr	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
title_full_unstemmed	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
title_sort	cardiac transthyretin-derived amyloidosis: an emerging target in heart failure with preserved ejection fraction?
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/95b6495b7e1045f9870bb1ae57637de7
work_keys_str_mv	AT sebastiaanhcklaassen cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction AT dirkjvanveldhuisen cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction AT hanslanienhuis cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction AT maartenpvandenberg cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction AT boukepchazenberg cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction AT petervandermeer cardiactransthyretinderivedamyloidosisanemergingtargetinheartfailurewithpreservedejectionfraction
_version_	1718372750241824768

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Ejemplares similares